While accumulating evidence supports the cardioprotective effects of SGLT2 inhibitors across various heart failure phenotypes [135,136,137,138,139,140] and increasingly within aortic stenosis (AS), robust data from prospective, AS-specific randomized trials remain limited. The gene discussed is SLC5A2; the disease is aortic valve stenosis.